Research progress on new drugs for the treatment of chronic hepatitis B virus infection
10.3760/cma.j.cn501113-20240521-00258
- VernacularTitle:慢性乙型肝炎病毒感染治疗新药物的研究进展
- Author:
Yingying YU
1
;
Jing LI
;
Wenxin WANG
;
Peiyao FAN
;
Fusheng WANG
Author Information
1. 中国科学技术大学附属第一医院（安徽省立医院），合肥 230001
- Publication Type:Journal Article
- Keywords:
Hepatitis B virus;
Chronic hepatitis B;
Hepatitis B surface antigen;
Functional cure
- From:
Chinese Journal of Hepatology
2025;33(5):493-499
- CountryChina
- Language:Chinese
-
Abstract:
Hepatitis B virus (HBV) infection is a major global public health problem. There will be about 257 million chronic HBV-infected patients worldwide, according to the World Health Organization's estimation by 2025. Currently, the main drugs for the treatment of chronic HBV infection are nucleos(t)ide analogues and pegylated interferon (PEG-IFN). However, previous research results show that whether it is nucleos(t)ide analogues and PEG-IFN-α monotherapy or combination therapy, or sequential combination therapy, the rate of hepatitis B surface antigen seroconversion in patients is low, and there is still a high risk of disease progression after a certain course of antiviral treatment. Therefore, to achieve the ambitious target of "eliminating viral hepatitis by 2030" set by the World Health Organization and help more hepatitis B patients achieve functional cure, a large number of new drugs have been developed and entered clinical trials. This paper summarizes and reviews the types, safety, and efficacy of new drugs to further promote advancements in the field of treatment of chronic HBV infection.
